csilab.net

What It Is

Dual-Brain Lab is a personal/professional site focused on the intersection of “clinical oncologists × AI.” Its core is not a general-purpose AI SaaS product, but a record of real-world collaboration with AI in clinical research, medical data analysis, and content production. The site also offers a “trial database,” positioned as a clinical-trial timeline knowledge base curated by frontline clinical oncologists.

Core Capabilities and Content

Based on the crawled content, the site mainly covers AI + clinical research practice, including topics such as MIMIC-IV, survival analysis, multi-omics, and the use of Claude Code in medical data analysis. The trial database includes phase II/III clinical trials cited in the current NCCN or CSCO guidelines, with data sources including ClinicalTrials.gov, PubMed, NCCN, and CSCO. It emphasizes traceability through PMID, NCT numbers, and guideline page references. Entries are already shown for multiple cancer types, including NSCLC, SCLC, gastric cancer, esophageal cancer, liver cancer, colorectal cancer, and breast cancer.

Pricing and Ease of Use

The main content does not mention pricing, subscriptions, trials, or an account system, so it currently appears to be publicly accessible. The site supports switching between Simplified Chinese and English, and also offers dark mode. As an information site, it has a relatively low reading barrier. However, if evaluated as a “tool,” there is no visible support for advanced search, APIs, bulk export, permission management, or structured downloads, so its level of tooling remains limited.

Strengths and Limitations

Its strengths are that the author has a clinical oncology background and selects topics that are very close to real research workflows. The site is also restrained in how it describes AI’s role, explicitly stating that “AI is a comrade-in-arms, not a replacement.” The trial database also transparently notes that it is currently a draft generated by an AI pipeline, has undergone automated cross-checking, but has not yet been reviewed item by item by clinicians. This level of transparency is commendable. The limitations are that it does not disclose the specific models used, verification process, accuracy metrics, update mechanism, or data privacy policy. Clinical data and efficacy figures should still be confirmed against the original literature and guidelines.

Who It’s For and Access from China

It is suitable for oncologists, clinical researchers, medical master’s/PhD students, and people who want to learn AI-assisted medical research workflows. It is especially useful as a reference for organizing trial leads and research methods. It is not suitable for direct automation of clinical decision-making or as a replacement for authoritative databases. Access from China cannot be confirmed from the crawled text, and payment information is not mentioned. Alternative or complementary tools include PubMed, ClinicalTrials.gov, the original NCCN/CSCO guidelines, and research search tools such as Elicit, Consensus, and Perplexity.